C2N Diagnostics is expanding blood-based biomarker testing for Alzheimer's pathology across Latin America and the Caribbean through a partnership with SouthGenetics. This addresses a critical gap: regions with aging populations, limited specialist capacity, and constrained imaging infrastructure now have earlier access to amyloid assessment before cognitive decline becomes clinically apparent.
Key Points
- Blood tests detect brain amyloid pathology before symptom onset
- Partnership covers nine countries with aging demographics and limited specialist access
- Enables earlier intervention timing with recently approved disease-modifying therapies
Longevity Analysis
Early detection of Alzheimer's pathology through accessible biomarkers represents a shift from reactive diagnosis to predictive assessment. Before a person develops symptoms, amyloid accumulation in the brain can be identified and monitored—creating a window for intervention before irreversible neurological changes occur. This is particularly significant in underserved regions where cognitive decline is often detected only after substantial neurological damage has already accumulated. The ability to identify at-risk individuals earlier, combined with emerging therapeutic options, changes the natural history of the disease for those who can access testing and treatment. The constraint has not been whether early detection matters; it has been whether early detection was practically available outside wealthy healthcare systems. This partnership begins to eliminate that barrier.
Original published by Longevity.Technology.